INTRODUCTION
propanoate. TA is a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. It is used in the treatment of HIV infection and chronic hepatitis B. It is closely related to the commonly used reverse-transcriptase inhibitor tenofovir disproxil, TA has greater antiviral activity and better distribution into lymphoid tissues than that tenofovir disproxil. Literature survey reveals that various HPLC [4] [5] LC-MS, 6 HPTLC 7-8 method and have been reported for the estimation of Tenofovir disproxil fumerate and Lamuvidine. The present study illustrates development and validation of a simple, accurate and precise procedure for "Development and validation of RP-HPLC method for the simultaneous estimation of lamivudine, tenofovir alafenamide and dolutegravir bulk and their combined dosage form".
MATERIALS AND METHODS

Chemicals and reagents
Working standard of Lamivudine, Dolutegravir and Tenofovir Alafenamide was obtained as gift sample from Hetero Laboratories, Hyderabad, India. Reagents used were KH 2 PO 4 . AR Grade, Qualizines, India. HPLC graded acetonitrile Qualizines India and Triple distilled water for the entire study.
Instrumentation
The method development and validation were carried out by using HPLC Agilent separation module model, it was equipped with auto-sampler with injection volume 10 μl, column used was Agilent C18 (250 × 4.6 mm, i.d., 5 μm) column and data recorded using EZ chrome elite software.
Chromatographic conditions
Various combinations of mobile phases were screened and finally, the mobile phase consisting of 0.05M phosphate buffer pH 6.2 (solvent A) and acetonitrile (solvent B) 60:40 v/v was set with isocratic programming for 15 min optimized at a flow rate of 1 ml/min, at 260 nm wavelength, the injection volume of 10 μL and ambient temperature was maintained during the entire process to obtain symmetric peaks of Lamivudine,Tenofovir alafenamide and Dolutegravir.
Preparation of Solutions
Diluent: Mix an equal volume of acetonitrile and water in the ratio of 1:1 which was used as a Diluent.
Mastanamma, et al.: RP-HPLC Method For The Simultaneous Estimation
Preparation of 0.05M Phosphate buffer of pH 6.2
Weigh accurately about of 1.37g of monobasic potassium dihdro-orthophosphate (KH2PO4) and transfer into1000 ml volumetric flask containing 200ml distilled water, shake for 5 mns and final volume was made up with distilled water, sonicate for 15 mns and ph 6.2 was adjusted with orthophosphoric acid.
Mobile Phase
0.05M phosphate buffer pH 6.2 and acetonitrile (60:40)v/v was prepared and filtered through 0.45micron membrane filter to remove the impurities and sonicate using ultrasonicator to remove the un dissolved gases.
Preparation of standard stock solution
A standard stock solution was prepared accurately weigh and transfer 10 mg of lamivudine, tenofovir alafenamide and dolutegravir into a 10 ml clean dry volumetric flask and dissolved in 7 ml of diluent after vigorous shaking the volume was made with up to the mark with diluent to get conc. of 1000µg/ml for each drug .from this 5 ml was transferred to 50 ml volumetric flask and volume made up with the mobile Phase to obtain the concentration of 100 μg/ml of lamivudine, tenofovir alafenamide and dolutegravir respectively.
Chromatographic condition
Agilent C 18 (250×4.6 mm I.D; 5 μm) column is used for detection at a wavelength of 260nm, using 0.05M phosphate buffer pH 6.2 (solvent A) and acetonitrile (solvent B) 60:40 v/v) in a isocratic elution mode as a mobile phase. The contents of the mobile phase was degassed, with a helium sparge for 15 min and filtered through vaccum filtration pumped from the respective solvent reservoirs to the column at a flow rate of 1 mL/min. The column temperature was maintained at 30 o c and run time was 15 mins. The injection volume of sample was 10 μl. Retention times for the three compounds were found to be 3.09 min, 6.19 min and 9.61min for lamivudine, tenofovir alafenamide and dolutegravir respectively. The optimized chromatogram and the conditions are shown [ Table 1 ] and [ Figure 4 ].
Construction of calibration curves for LAM, TAF, DOL
For the construction of calibration curves, a series of aliquots were prepared from the above stock solution by transferring 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml into a 10ml volumetric flask and final volume was made with mobile phase to get the conc. of 10-80 µg/ml of each drug. Each concentration was injected 6 times into the column and each time retention time and peak area of LAM, TAF and DOL was noted. Construct the calibration curves separately by taking concentration (µg/ml) on the x-axis and average peak area on the y-axis for the drugs [ Figure 5 ]. From the calibration curves, regression equations were calculated, these regression equations were used to calculate the amount of LAM, TAF and DOL present in the commercial dosage form.
Preparation of sample solution
Laboratory synthetic mixture was prepared by accurately weighed Lamivudine (150mg), Tenofovir alafenamide (25mg), Doltegravir (50 mg) and excipients were mix well in a mortor and pestle from this powder equivalent to 10mg of Tenofovir alfenamide contained 20mg of Doltegravir and Mastanamma, et al.: RP-HPLC Method For The Simultaneous Estimation 60 mg of Lamivudine was taken into a 10 ml volumetric flask and dissolved with diluents to get the conc of 1000µg/mL of tenofovir alafenamide from this test solution was prepared by diluting the above sample stock solution which contains 10µg/mL of TAF, 20 µg/mL of DOL, 60µg/ ml LAM, by using a mobile phase. The test solution was injected 6 times into the column, each time peak area and retention time was noted. The % of drug content in the Laboratory synthetic mixture was estimated by using regression equation and the result obtained were noted as shown in the [ Table 2 ]
Method validation
The developed method for simultaneous estimation of Lamivudine, Tenofovir alafenamideb and Dolutegravir has been validated in accordance with the International Conference on Harmonization guidelines.
Linearity
Several aliquots of standard stock solution of Lamivudine,Tenofovir alafenamide and Dolutegravir were taken in different 10 ml volumetric flask and diluted up to the mark with the mobile phase such that their final concentrations were 10-80μg/ml for LAM, 10-80μg/ml for TAF, 10-80μg/ml and respectively. Peak areas were plotted against the corresponding concentrations to obtain the calibration graph for each compound as shown in [Table 3 
Accuracy
The accuracy of the method for assay determination was achieved at three concentration levels of 50%, 100%, and 150% for Lamivudine,Tenofovir alafenamide, Dolutegravir. Known amount of standard drug concentration was added to the pre analysed sample concentration and mean peak area was determined. The mean percentage recovery values are shown in [ Table 4 ]. Precision: Precision is the degree of repeatability of an analytical method under normal operating condition. Precision is of 3 types. 1. system precision. 2. method precision. 3. intermediate precision.
a. inter-day precision. Method precision was achieved by repeating the same procedure of preparation solution six times and injecting. System precision is checked by injecting using a standard chemical 
System Suitability
Six replicates of standard stock solution for each drug were injected sample containing Lamivudine, Tenofovir alafenamide, and Dolutegravir was given to evaluate equipment, electronics and analytical operations and samples suitability. Parameters calculated for system suitability were percentage of relative standard deviation of retention time, number of theoretical plates and tailing factor. Results found were given in [ Table 7 ] and within acceptable limits.
Robustness
To evaluate the robustness of the method, the chromatographic conditions were deliberately altered and degree of reproducibility was evaluated. During robustness testing each condition was varied separately, all other conditions being held constant at the optimized values. Robustness of the proposed method was assessed with respect to small alterations in the flow rate (1.0 ± 0.2ml/min), organic composition and the results obtained from as shown the [ Table 8 ].
Selectivity
Selectivity test determines the effect of excipients on the assay result.
To determine the selectivity of the method, a standard solution of Lamivudine, Tenofovir alafenamide and Dolutegravir, excipient solution and blank solutions were run in the instrument one after another. The results of the tests proved that the components other than the drug did not produce any detectable signal at the retention time of Lamivudine, Tenofovir alafenamide and Dolutegravir. In [ Figure 6 ] and [ Figure   substance to ensure that the analytical system is working properly. In this peak area and percentage of the drug of six determination is measured and percentage relative standard deviation should be calculated.
In method precision, a homogenous sample of the single batch should be analyzed 6 times. The indicates weather a method is giving a constant result for a single batch. In this analysis the inject the sample six times and calculate the % RSD and the results are shown in [ Table 5 ].
LOD and LOQ
LOD:
It is the lowest amount of analyte in a sample that can be detected but not necessarily quantities as an exact value under the stated, experimental conclusions. The detection limit is usually expressed as the concentration of the analyte. The standard deviation and response of the slope. LOD = 3.3*standard deviation (6)/s
LOQ:
The quantitation limit of an analytical procedure is the lowest amount of an analyte of a sample which can be quantitatively determined with suitable precision and accuracy. The standard deviation and response of the slope and the results obtained.
LOQ= 10* standard deviation (6)/s
The results of LOD and LOQ are shown in the [ Table 6 ]. 
System suitability
Six replicates of standard stock solution containing Lamivudine, Tenofovir alafenamide and Dolutegravir were given to evaluate equipment, electronics, and analytical operations and samples suitability. Parameters calculated for system suitability were a number of theoretical plates, tailing factor, resolution, retention time, and area. The results as shown in [ Table 7 ]. Indicates the system is a suitable or proposed method.
LOD and LOQ
The LOD and LOQ were measured, LOD value of LAM, TAF and DOL was found to be 0.5603, 0.3940 and 1.3532µg/mL, respectively. The LOQ values were found to be 1.5038, 0.9940 and 1.6100 for LAM, TAF and DOL respectively. The statistical data were presented in [ Table 6 ].
Recovery
The percentage recovery was calculated by preparing standard drug concentrations of LAM, TAF and DOL with concentration levels of 7] shows the chromatogram of Lamivudine, Tenofovir alafenamide and Dolutegravir mobile phase and placebo respectively. There were no interfering peaks at retention time of Lamivudine, Tenofovir alafenamide and Dolutegravir).
RESULTS AND DISCUSSION
Optimization of chromatographic conditions
A simple, accurate and precise RP-HPLC method was developed and validated for the simultaneous estimation of Lamivudine, Tenofovir alafenamide and Dolutegravir. A mobile phase consisting of .05M phosphate buffer (solvent A) pH 6.2 and acetonitrile (solvent B) 60:40v/v was set with isocratic programming for 15 min. Chromatographic conditions were optimized for mobile phase using Agilent C 18 (250 × 4.6 mm, i.d., 5 μm) column at a flow rate of 1 ml/min. Effluents were detected at 260 nm by variable wavelength PDA detector. Column compartment temperature was in ambient. Chromatogram of Lamivudine,Tenofovir alafenamide, and Dolutegravir at optimized chromatographic condition was shown in [ Figure 4 ].
Selectivity
[ Figure 6 and 7] shows the chromatogram of blank, sample. There were no interfering peaks at retention time of LAM, TAF and DOL was observed. Table 4 ].
Precision
Precision is expressed as the closeness of agreement between a series of measurements obtaining from multiple sampling of the same homogeneous sample. Six replicate injections of a known concentration of LAM 60,70,80 (µg/ml), TAF 10,20,30 (µg/ml) and DOL 20,30,40 (µg/ml) have been analyzed by injecting them into a HPLC column on the same day and on consecutive days. From the results obtained, % RSD was calculated and was found to be within the limits <2. The results are given in [ Table 5 ].
Robustness
Robustness of the proposed analytical method is a measure of its capacity to remain unaffected, and it reflects the reliability of the analysis with respect to deliberate changes in the parameters such as flow rate (1.0 ± 0.2ml/min), column temperature (ambient), mobile phase ratio and pH of the mobile phase. The parameters chosen for the study of robustness is the flow rate and mobile phase composition. From the results obtained, there were no significant changes observed at the end of the study. The results are given in [ Table 8 ].
CONCLUSION
In this study, a simple, fast and reliable HPLC method was developed for the simultaneous estimation of Lamivudine, Tenofovir Alafenamide and Dolutegravir. The simultaneous estimation of Lamivudine, Tenofovir Alafenamide and Dolutegravir could be achieved successfully, although there was a great difference in polarity between the compounds. it shows that the validated method was specific.
From the results, it can be concluded that the method has been successfully applied for the analysis of marketed tablets and can be used for the routine analysis of formulations containing any one of the selected drugs or their combinations, without any alteration in the assay. Since the method was successfully applied for the estimation of selected drugs in bulk as well; therefore, this method can also be adopted for the study of pharmaceutical release patterns of the drugs while designing new dosage forms. This method can be used as a routine quality control method for triple combined dosage forms. The method also shows a good performance with respect to specificity, sensitivity, linearity, accuracy and precision.
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